phase II trial of the FOLFOX regimen as 1st line treatment in adenocarcinoma of unknown primary
- Conditions
- Neoplasms
- Registration Number
- KCT0000410
- Lead Sponsor
- Korea Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 32
Newly diagnosed adenocarcinoma of unknown primary origin (histologic diagnosis)
Tests described below to find out the origin or cancer should be performed.'
complete blood count, chemistry, urine analysis
chest & abdomen-pelvis enhanced CT
Mammography in case of female patient (Breast MRI if clincally suspected breast cancer)
Endoscopy (Stomach, colon)
Other nessesary tests about the suspected primary
Exclusion of suspected origin through review of histopathologic findings as follows:
Estrogen or progesterone receptor positive in female patients
TTF (Thyroid transcription factor 1) positive
PSA (Prostate specific antigen) positive in male patients
Age: over 20 years old
Axillary lymph node metastasis in female patient
papillary adenocarcinoma of abdominal cavity in female patient
bone adenocarcinoma with elevating PSA in male patient
Potentially resectable metastatic cancer
Brain metastasis
History of surgery of malignant tumor
cancer other than adenocarcinoma (ex. leiomyosarcoma, lymphoma) or secondary malignancy.
(basal cell skin cacner or uterine cervix intraepithelial cell carcinoma that were previously successfully treated were exceptions)
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method overall response rate;overall survival